4.6 Article

Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International Workshop

期刊

JOURNAL OF BONE AND MINERAL RESEARCH
卷 37, 期 12, 页码 2568-2585

出版社

WILEY
DOI: 10.1002/jbmr.4691

关键词

PTH; VIT D; FGF23; CELL; TISSUE SIGNALING-ENDOCRINE PATHWAYS; PARATHYROID-RELATED DISORDERS; DISORDERS OF CALCIUM; PHOSPHATE METABOLISM

资金

  1. Takeda
  2. Amolyt
  3. Ascendis
  4. Calcilytix

向作者/读者索取更多资源

This clinical practice guideline provides evidence-based recommendations for the prevention, diagnosis, and management of hypoparathyroidism. Evaluating serum PTH within 12 to 24 hours post total thyroidectomy can predict the development of permanent postsurgical hypoparathyroidism. Genetic testing may be helpful for individuals with nonsurgical hypoparathyroidism.
This clinical practice guideline addresses the prevention, diagnosis, and management of hypoparathyroidism (HypoPT) and provides evidence-based recommendations. The HypoPT task forces included four teams with a total of 50 international experts including representatives from the sponsoring societies. A methodologist (GG) and his team supported the taskforces and conducted the systematic reviews. A formal process following the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology and the systematic reviews provided the structure for seven of the guideline recommendations. The task force used a less structured approach based on narrative reviews for 20 non-GRADEd recommendations. Clinicians may consider postsurgical HypoPT permanent if it persists for >12 months after surgery. To predict which patients will not develop permanent postsurgical HypoPT, we recommend evaluating serum PTH within 12 to 24 hours post total thyroidectomy (strong recommendation, moderate quality evidence). PTH > 10 pg/mL (1.05 pmol/L) virtually excludes long-term HypoPT. In individuals with nonsurgical HypoPT, genetic testing may be helpful in the presence of a positive family history of nonsurgical HypoPT, in the presence of syndromic features, or in individuals younger than 40 years. HypoPT can be associated with complications, including nephrocalcinosis, nephrolithiasis, renal insufficiency, cataracts, seizures, cardiac arrhythmias, ischemic heart disease, depression, and an increased risk of infection. Minimizing complications of HypoPT requires careful evaluation and close monitoring of laboratory indices. In patients with chronic HypoPT, the panel suggests conventional therapy with calcium and active vitamin D metabolites as first-line therapy (weak recommendation, low-quality evidence). When conventional therapy is deemed unsatisfactory, the panel considers the use of PTH. (c) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据